59515-34-3

Upstream product

• 35350-37-9 methyl 4-[[4-(methoxycarbonyl)-2-nitrophenyl]disulfanyl]-3-nitrobenzoate 
• 14719-83-6 methyl 3-nitro-4-chlorobenzoate 
• 329-59-9 4-fluoro-3-nitro-benzoic acid methyl ester 
• 49706-71-0 bis(2-nitro-4-carboxyphenyl) disulfide 

Downstream Products

• 162010-78-8 4-chlorosulfonyl-3-nitrobenzoic acid methyl ester 
• 162010-79-9 4-(Aminosulfonyl)-3-nitrobenzenecarboxylic acid, methyl ester 
• 199535-36-9 3-Amino-4-sulfamoyl-benzoic acid methyl ester 

Relevant academic research and scientific papers

INDOLE DERIVATIVE USED AS CRTH2 INHIBITOR

The present application discloses an indole as represented by formula (I) used as a CRTH2 inhibitor, and a pharmaceutically acceptable salt or tautomer of the indole, and an application of same in treating a disease related to a CRTH2 receptor.

As CRTH2 inhibitor of indole compounds (by machine translation)

The application discloses a formula (I) as shown in CRTH2 inhibitor of indole compound or its pharmaceutically acceptable salt, and their use in the treatment with the CRTH2 receptor-related diseases in the application. (by machine translation)

Utility of the 2-Nitrobenzenesulfonamide Group as a Chemical Linker for Enhanced Extracellular Stability and Cytosolic Cleavage in siRNA-Conjugated Polymer Systems

Herein we report the 2-nitrobenzenesulfonamide group as a new chemical linker that responds to the difference in redox potential across the cellular membrane, toward the construction of siRNA–polymer conjugates. PEG-conjugated to siRNA via the 2-nitrobenz

Aromatase inhibitor compounds and uses thereof

The invention concerns the use of a compound of formula (I) inhibitor of aromatase for the preparation of a pharmaceutical formulation intended for treatment of cancer or psoriasis. It equally relates to compounds of formula (I), notably for their use as active ingredients of a medication.

COMPOUNDS HAVING A FUSED, BICYCLIC MOIETY FOR BINDING TO THE MINOR GROOVE OF DSDNA

The present invention is directed to the means by which to alter the binding affinity and/or specificity of a compound with a sequence of DNA in the minor groove of a double-strand thereof. More particularly, the present invention is directed to a synthetic and/or non-naturally occurring compound (e.g., an analog of a polyamide oligomer or polymer) which contains at least one hydrogen bond donor moiety and at least one hydrogen bond acceptor moiety, wherein the latter moiety or "building block" has a fused, bicyclic structure which is heteroaromatic, said structure having a heteroatom therein which acts as a hydrogen bond acceptor to bind guanine in the minor groove of the dsDNA sequence, and which is incapable of forming a tautomer. In one particular embodiment of the synthetic and/or non-naturally occurring compound, the fused, bicyclic structure occupies an initial or first terminal position within the compound.